Merrimack Pharmaceuticals Story Overview

MACK -- USA Stock  

USD 8.40  0.23  2.67%

Macroaxis does not monitor all media channels or aggregates social signals for Merrimack Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Merrimack Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Merrimack Pharmaceuticals. Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance.
Acquisition by John Mendelsohn of 7500 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Filed transaction by Merrimack Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by John Mendelsohn, the corporate stakeholder, on December 7, 2017. This event was filed by Merrimack Pharmaceuticals with SEC on 2017-09-15. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on December 7, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.95% . The trading delta at closing time when the story was published against the current closing price is 17.08% .

Similar stores for Merrimack Pharmaceuticals

That Will Motivate You Today- Orion Group Holdings, Inc. , Eaton Vance New York Municipal Income Trust ...Thestreet News
The Stock Street Full coverage
over a week ago at http://yankeeanalysts.com 
What Are The Technicals Telling Us About Merrimack Pharmaceuticals Inc
news
Yankee AnalystsFull coverage
over two weeks ago at http://usindexlive.com 
On May, 9 The EPS for Merrimack Pharmaceuticals, Inc. Expected At -1.28
news
US Index LiveFull coverage
over three weeks ago at http://mostvolatilestocks.com 
Stock Performance Activity to Track Merrimack Pharmaceuticals, Inc.
news
MostVolatileStocks Full coverage
over a month ago at http://kgazette.com 
Analysts See -1.28 EPS for Merrimack Pharmaceuticals, Inc. Nfc Investments Lifted By 2.06 Million Its ...
news
Key GazetteFull coverage
over a month ago at http://mostvolatilestocks.com 
Analysts Call Attention Merrimack Pharmaceuticals, Inc.
news
MostVolatileStocks Full coverage
over a month ago at http://utahherald.com 
Merrimack Pharmaceuticals, Inc. Reaches 8.57 After 3.00 percent Up Move Global Med Technologies Has 1.23 ...
news
UtahHerald.comFull coverage
over a month ago at http://malibureport.com 
Is Merrimack Pharmaceuticals, Inc. a Buy The Stock Rises Again
news
The Malibu ReportMerrimack Pharmaceuticals, Inc. Increases to 8.29 on Apr, 7 US Index LiveMerrimack Pharmaceuticals Inc. Shares Rating Upgrade by Vetr Inc. BangaloreWeeklyFull coverage
over a month ago at www.macroaxis.com 
Exercise or conversion by Edward Stewart of 5000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Merrimack Pharmaceuticals officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at http://bzweekly.com 
Discovery Communicatns New Shares Declined While Yakira Capital Management Decreased Stake Tokio ...
news
BZ WeeklyFull coverage
over two months ago at http://www.thewellesleysnews.com 
Analyst Opinion Summary Merrimack Pharmaceuticals, Inc. , Nuveen Real Estate Income Fund
news
Analyst JournalFull coverage
over three months ago at http://www.dispatchtribunal.com 
Reviewing Merrimack Pharmaceuticals and Prana Biotechnology
patch News
Dispatch TribunalFull coverage
over three months ago at http://www.truebluetribune.com 
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Merrimack Pharmaceuticals Stock Price
news
TrueBlueTribuneMany Investors Taking a Second Look at Merrimack Pharmaceuticals, Inc. After Recent Moves Nelson ResearchFull coverage

Did you try this?

Run Portfolio Diagnostics Now
   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Portfolio Diagnostics

Number of Employees

Number of Employees Comparative Analysis
  Number of Employees 
      Merrimack Pharmaceuticals Comparables 
Merrimack Pharmaceuticals is currently under evaluation in number of employees category among related companies. Number of Employees shows total number of permanent full time and part time employees working for a given company and processed through its payroll.

Peers

Merrimack Pharmaceuticals Related Equities
NK  2.60 %   
0%
43.0%
DRNA  0.44 %   
0%
7.0%
DOVA  0.24 %   
0%
4.0%
DMTX  0.00 %   
0%
0%
DMPI  0.51 %   
8.0%
0%
DRRX  1.05 %   
17.0%
0%
VBLT  1.4 %   
23.0%
0%
DNLI  1.77 %   
29.0%
0%
VCEL  2.11 %   
35.0%
0%
VBIV  5.97 %   
100.0%
0%
Please see also Merrimack Pharmaceuticals Hype Analysis, Merrimack Pharmaceuticals Correlation and Merrimack Pharmaceuticals Performance. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.